HOME >> BIOLOGY >> NEWS
'Search and destroy' protein turns tables on HIV

MINNEAPOLIS / ST. PAUL -- A human protein that mutates the AIDS virus (HIV) and holds potential for keeping the disease at bay has been discovered and its function described by a team led by Reuben Harris of the University of Minnesota. The new protein (called APOBEC3F) and one described previously (APOBEC3G) can directly mutate HIV. Such proteins--called retroviral restrictors--may contribute to HIV resistance in some people. Harris, an assistant professor of biochemistry, molecular biology and biophysics, and colleagues at the university report the discovery in a paper to be published online June 24 in the journal Current Biology.

In an individual infected with HIV, the virus uses the human cellular machinery to assemble new viral particles. But sometimes those particles contain time bombs: human APOBEC proteins that hitch a ride in the particles and mutate the virus' genetic material after it has infected a new host cell.

Unfortunately for us, the AIDS virus has evolved a counterdefense. It produces a protein called VIF (viral infectivity factor), which triggers the destruction of the retroviral restrictors, thereby preventing mutations from occurring. What scientists don't know is whether some HIV-resistant people have forms of the retroviral restrictor proteins that can evade VIF and avoid destruction.

When DNA from the HIV virus is inserted into the human genome, it sometimes bears the scars of encounters with the APOBEC proteins. The two proteins leave different mutational "signatures," and the signature of APOBEC3F occurs more often.

This, said Harris, indicates that it might be less vulnerable to the virus' VIF counterdefense. Indeed, using a model HIV system, Harris and colleagues showed that APOBEC3F was less susceptible to VIF than APOBEC3G. Moreover, said Harris, the two proteins can account for all the anti-HIV mutational signatures apparent in HIV DNA of AIDS patients. But what function the proteins perform in non-H
'"/>

Contact: Deane Morrison
morri029@umn.edu
612-624-2346
University of Minnesota
24-Jun-2004


Page: 1 2

Related biology news :

1. New molecular link key to cellular proteins involved in cancer progression, other diseases
2. Researchers identify protein promoting vascular tumor growth
3. UCI scientists successfully target key HIV protein; breakthrough may lead to new drug therapies
4. Experimental drug shown to block mutant protein causing blood disease
5. Loss of the neuronal adhesion protein d-catenin leads to severe cognitive dysfunction
6. Images of tail of protein needed for cell multiplication suggest anticancer drug targets
7. New dye directly reveals activated proteins in living cells
8. Disruption of protein-folding causes neurodegeneration, mental retardation
9. A new protein is discovered to play a key role in cancer progression
10. Optimizing proteins death domain halts leukemia in laboratory study
11. Stuck on you: Scientists lay bare secrets of bacterial attachment proteins

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Search and destroy protein turns tables HIV

(Date:8/18/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ... "Global Biometric Authentication & Identification Market: Focus On ... 2015-2020" report to their offering. ... market is expected to grow at an estimated ... generate over $25 billion (approximately) by 2020 as ...
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
Breaking Biology News(10 mins):Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
(Date:8/28/2015)... ... ... initial launch of FireflySci Inc. (FFS) in early 2015, the company continues to shake up ... the Fonz in a lab coat and Large Marge have been posted on the company’s ... , FireflySci is proud to be the only cuvette manufacturer is the world that has ...
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... SAN DIEGO , Aug. 27, 2015 ... second annual meeting of the Japan Society of HTLV-1, ... Science Institute Auditorium. The purpose of the Society is ... well as the development of medical technology and research ... health and welfare. "HUYA is proud to ...
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
Cached News: